What Happened?
San Francisco, CA-based Spruce-Biosciences Appointed Richard King as Chief Executive Officer
Date of management change: May 15, 2019
San Francisco, CA-based Spruce-Biosciences Appointed Richard King as Chief Executive Officer
Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Our wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage trials in adult patients with classic congenital adrenal hyperplasia (CAH), with a planned Phase 2 trial in pediatric classic CAH. We aim to advance the treatment paradigm for classic CAH with a well-tolerated, non-steroidal approach designed to offer markedly improved disease control and reduced steroid burden for patients. Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including a rare form of polycystic ovary syndrome (PCOS).
Richard King is Chief Executive Officer at Spruce Biosciences. Previously, Richard held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Dervan Ailbhe, Lazowski Nic, Davidson Tom, Heltai Gillian, Reddy Ravi, Ventura Pamela, Madabushi Vasu, Nelson Kim, Strong Vickie, Streicher Keith, Khasis Lev
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.